Please try another search
WASHINGTON - The U.S. Food and Drug Administration has granted approval to AstraZeneca (NASDAQ:AZN)'s Calquence (acalabrutinib), in combination with bendamustine and rituximab, for the treatment of...
Investing.com -- AstraZeneca (LON:AZN) in a stock exchange filing on Friday said that the FDA approved its drug Calquence (acalabrutinib) to treat previously untreated mantle cell lymphoma (MCL) in...
LONDON - AstraZeneca PLC (LSE:LON:AZN) has announced the appointment of two new Non-Executive Directors to its board. Rene Haas, CEO of Arm, and Birgit Conix, CFO of Sonova, will join the company...
WASHINGTON - AstraZeneca (NASDAQ:AZN)'s supplemental Biologics License Application (sBLA) for Imfinzi (durvalumab) has been accepted and given Priority Review by the U.S. Food and Drug Administration...
LONDON - AstraZeneca PLC (LSE/STO/Nasdaq: LON:AZN), the UK-based global biopharmaceutical company, has announced the appointment of Iskra Reic as its new Executive Vice President (EVP), International....
In 2024, six companies focused on immunology listed in the US. According to BioPharma Dive data, it was the highest total outside of oncology since 2021 when only seven of 104 newly listed companies...
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review